16. The method of claim 1, wherein the immune checkpoint inhibitor is administered intravenously. 17. The method of claim 1, wherein the first administration and the second administration further comprise an effective amount of a MEK inhibitor. 18. The method of claim 17, wherein the MEK inh...
6. The compound of claim 1 wherein the compound of formula II is selected from the group consisting of 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sulfonyl]piperidin-3-yl}amino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl carbamate, 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sul...
15.The method of claim 12, wherein the cancer therapy is a biochemotherapy. 16.The method of claim 12, further comprising, after the step of detecting, continuing with the cancer therapy if the amount of B-RAF gene after the cancer therapy is less than the amount of the mutant B-RAF ...
5.The platform system of claim 1, wherein said mounting plate comprises:an under surface configured to be disposed to face the bottom surface of the cooking space; anda plurality of adjustable mounts, each being configured to adjust its respective height so as to collectively adjust a space bet...
67. The method of claim 66, wherein the compound is of formula: 68. The method of claim 66, wherein the suitable base is lithium hydroxide. 69. The method of claim 66, wherein the suitable acid is acetic acid.Description: PRIORITY The present application claims priority under 35 U.S...
11. The method of claim 8, wherein said cellular transformation phenotype is induced by a ras oncogene product. Description: BACKGROUND OF THE INVENTION Field of the Invention The present invention relates, in general, to methods of inducing a therapeutic effect. In particular, the present invent...
31. The method of claim 29, wherein the cancer is a carcinoma. 32. The method of claim 31, wherein the carcinoma is squamous cell carcinoma. 33. The method of claim 31, wherein the carcinoma is adenoma or adenocarcinoma. 34. The method of claim 29, wherein the cancer is breast, ov...
8.The process according to claim 1, wherein compound (A) has formula (1)the process comprising reacting a compound of formula (1) with 4-chloro-N-methyl-2-pyridine carboxamide in the presence of a base to obtain sorafenib 9.The process according to claim 8, wherein compound of formula ...
I claim: 1. In a process of manufacturing paper filled with a filler comprising a substantially waterinsoluble carbonate, the steps of bringing into substantially intimate contact materials comprising substantially water-insoluble carbonate and a copper compound selected from a group consisting of copper...
2.The combination according to claim 1 wherein at least one of the exterior surfaces of said cushioning cap contains indicia. 3.The combination according to claim 1 wherein said solid body of resilient material is comprised of at least one member selected from the group consisting of expanded ...